A multiCenter phase I study of aUtologous CD19 CAR T cElls for therapy refractory chronic GvHD (CURE-cGvHD)

2025-524468-40-00 Protocol CURE-cGvHD Human pharmacology (Phase I) - Other Authorised, recruiting

Start 9 Jun 2026 · Status Authorised, recruiting · 1 EU/EEA countries · 6 sites · Protocol CURE-cGvHD

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruiting
Participants planned 14
Countries 1
Sites 6

chronic Graft-versus-Host-Disease (cGvHD)

Key facts

Sponsor
Universitaetsklinikum Erlangen AöR
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
9 Jun 2026 → ongoing
Decision date (initial)
2026-03-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

chronic Graft-versus-Host-Disease (cGvHD)

VersionLevelCodeTermSystem organ class
27.0 LLT 10068907 CGVHD 10021428

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitaetsklinikum Erlangen AöR

Sponsor organisation
Universitaetsklinikum Erlangen AöR
Address
Maximiliansplatz 2, Innenstadt Innenstadt
City
Erlangen
Postcode
91054
Country
Germany

Scientific contact point

Organisation
Universitaetsklinikum Erlangen AöR
Contact name
Prof. Dr. med. Silvia Spörl

Public contact point

Organisation
Universitaetsklinikum Erlangen AöR
Contact name
Prof. Dr. med. Silvia Spörl

Locations

1 EU/EEA country · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Authorised, recruiting 14 6
Rest of world 0

Investigational sites

Germany

6 sites · Authorised, recruiting
Universitaetsklinikum Koeln AöR
Innere Medizin 1, Kerpener Strasse 62, Lindenthal, Cologne
Universitaetsklinikum Regensburg AöR
Innere Medizin III, Franz-Josef-Strauss-Allee 11, Grass-Oberisling, Regensburg
Universitaetsklinikum Wuerzburg AöR
Innere Medizin II, Oberduerrbacher Strasse 6, Grombuehl, Wuerzburg
Charite Universitaetsmedizin Berlin KöR
Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Hindenburgdamm 30, Lichterfelde, Berlin
Universitaetsklinikum Augsburg
II. Medizinische Klinik, Stenglinstrasse 2, Kriegshaber, Augsburg
Universitaetsklinikum Erlangen AöR
Medizinische Klinik 5, Ulmenweg 18, Innenstadt, Erlangen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2026-06-09

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-12-19 Germany Acceptable
2026-03-27
2026-03-27